Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.

Clinical pharmacology and therapeutics - 1 Oct 2005

Fux Richard, Mörike Klaus, Pröhmer Anne M T, Delabar Ursula, Schwab Matthias, Schaeffeler Elke, Lorenz Gernot, Gleiter Christoph H, Eichelbaum Michel, Kivistö Kari T

Abstract excerpt

OBJECTIVE: Our objective was to study the impact of the cytochrome P450 (CYP) 2D6 polymorphism on the tolerability of metoprolol in a real-life primary care setting. The adverse effects studied comprised effects related to the central nervous system, cardiovascular effects, and sexual dysfunction. METHODS: Patients in whom treatment with metoprolol was considered were enrolled into this prospective, 6-week...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hypertension

Share to Metoprolol

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 16198657
DOI: 10.1016/j.clpt.2005.07.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.PMID 16198657Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.Semantic proximity Read ↗

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.Semantic proximity Read ↗

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.Semantic proximity Read ↗

[Rationale and methods of the UNAMET study (dose- and CYP2D6-genotype-dependent adverse drug reactions of metoprolol)--a contribution to quality improvement in pharmacotherapy].Semantic proximity Read ↗

Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.Semantic proximity Read ↗

Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol TartrateSemantic proximity Read ↗

The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.Semantic proximity Read ↗

Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.Semantic proximity Read ↗

Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.Semantic proximity Read ↗

Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.